Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
PLoS Pathog ; 20(4): e1011906, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38669269

RESUMEN

The apicomplexan parasite Cryptosporidium is a leading cause of childhood diarrhea in developing countries. Current treatment options are inadequate and multiple preclinical compounds are being actively pursued as potential drugs for cryptosporidiosis. Unlike most apicomplexans, Cryptosporidium spp. sequentially replicate asexually and then sexually within a single host to complete their lifecycles. Anti-cryptosporidial compounds are generally identified or tested through in vitro phenotypic assays that only assess the asexual stages. Therefore, compounds that specifically target the sexual stages remain unexplored. In this study, we leveraged the ReFRAME drug repurposing library against a newly devised multi-readout imaging assay to identify small-molecule compounds that modulate macrogamont differentiation and maturation. RNA-seq studies confirmed selective modulation of macrogamont differentiation for 10 identified compounds (9 inhibitors and 1 accelerator). The collective transcriptomic profiles of these compounds indicates that translational repression accompanies Cryptosporidium sexual differentiation, which we validated experimentally. Additionally, cross comparison of the RNA-seq data with promoter sequence analysis for stage-specific genes converged on a key role for an Apetala 2 (AP2) transcription factor (cgd2_3490) in differentiation into macrogamonts. Finally, drug annotation for the ReFRAME hits indicates that an elevated supply of energy equivalence in the host cell is critical for macrogamont formation.


Asunto(s)
Criptosporidiosis , Cryptosporidium , Estadios del Ciclo de Vida , Proteínas Protozoarias , Criptosporidiosis/parasitología , Criptosporidiosis/tratamiento farmacológico , Proteínas Protozoarias/metabolismo , Proteínas Protozoarias/genética , Estadios del Ciclo de Vida/efectos de los fármacos , Cryptosporidium/efectos de los fármacos , Cryptosporidium/genética , Cryptosporidium/metabolismo , Factores de Transcripción/metabolismo , Factores de Transcripción/genética , Animales , Humanos , Bibliotecas de Moléculas Pequeñas/farmacología
2.
mBio ; 14(5): e0121523, 2023 Oct 31.
Artículo en Inglés | MEDLINE | ID: mdl-37646514

RESUMEN

IMPORTANCE: Malaria parasites export hundreds of proteins to the cytoplasm of the host red blood cells for their survival. A five amino acid sequence, called the PEXEL motif, is conserved among many exported proteins and is thought to be a signal for export. However, the motif is cleaved inside the endoplasmic reticulum of the parasite, and mature proteins starting from the fourth PEXEL residue travel to the parasite periphery for export. We showed that the PEXEL motif is dispensable for export as long as identical mature proteins can be efficiently produced via alternative means in the ER. We also showed that the exported and non-exported proteins are differentiated at the parasite periphery based on their mature N-termini; however, any discernible export signal within that region remained cryptic. Our study resolves a longstanding paradox in PEXEL protein trafficking.


Asunto(s)
Plasmodium , Proteínas Protozoarias , Proteínas Protozoarias/genética , Proteínas Protozoarias/metabolismo , Plasmodium/genética , Transporte de Proteínas , Eritrocitos/parasitología , Retículo Endoplásmico/metabolismo , Plasmodium falciparum/metabolismo
3.
J Cell Sci ; 136(6)2023 03 15.
Artículo en Inglés | MEDLINE | ID: mdl-36744402

RESUMEN

N-terminal acetylation is a common eukaryotic protein modification that involves the addition of an acetyl group to the N-terminus of a polypeptide. This modification is largely performed by cytosolic N-terminal acetyltransferases (NATs). Most associate with the ribosome, acetylating nascent polypeptides co-translationally. In the malaria parasite Plasmodium falciparum, exported effectors are thought to be translated into the endoplasmic reticulum (ER), processed by the aspartic protease plasmepsin V and then N-acetylated, despite having no clear access to cytosolic NATs. Here, we used inducible gene deletion and post-transcriptional knockdown to investigate the primary ER-resident NAT candidate, Pf3D7_1437000. We found that it localizes to the ER and is required for parasite growth. However, depletion of Pf3D7_1437000 had no effect on protein export or acetylation of the exported proteins HRP2 and HRP3. Despite this, Pf3D7_1437000 depletion impedes parasite development within the host red blood cell and prevents parasites from completing genome replication. Thus, this work provides further proof of N-terminal acetylation of secretory system proteins, a process unique to apicomplexan parasites, but strongly discounts a promising candidate for this post-translational modification.


Asunto(s)
Acetiltransferasas , Retículo Endoplásmico , Plasmodium falciparum , Acetiltransferasas/metabolismo , Retículo Endoplásmico/metabolismo , Péptidos/metabolismo , Plasmodium falciparum/enzimología , Procesamiento Proteico-Postraduccional , Proteínas Protozoarias/metabolismo
4.
Artículo en Inglés | MEDLINE | ID: mdl-33753338

RESUMEN

The intestinal protozoan Cryptosporidium is a leading cause of diarrheal disease and mortality in young children. There is currently no fully effective treatment for cryptosporidiosis, which has stimulated interest in anticryptosporidial development over the last ∼10 years, with numerous lead compounds identified, including several tRNA synthetase inhibitors. Here, we report the results of a dairy calf efficacy trial of the methionyl-tRNA (Cryptosporidium parvum MetRS [CpMetRS]) synthetase inhibitor 2093 and the spontaneous emergence of drug resistance. Dairy calves experimentally infected with Cryptosporidium parvum initially improved with 2093 treatment, but parasite shedding resumed in two of three calves on treatment day 5. Parasites shed by each recrudescent calf had different amino acid-altering mutations in the gene encoding CpMetRS (CpMetRS), yielding either an aspartate 243-to-glutamate (D243E) or a threonine 246-to-isoleucine (T246I) mutation. Transgenic parasites engineered to have either the D243E or T246I CpMetRS mutation using CRISPR/Cas9 grew normally but were highly 2093 resistant; the D243E and T246I mutant-expressing parasites, respectively, had 2093 half-maximal effective concentrations (EC50s) that were 613- and 128-fold that of transgenic parasites with wild-type CpMetRS. In studies using recombinant enzymes, the D243E and T246I mutations shifted the 2093 IC50 >170-fold. Structural modeling of CpMetRS based on an inhibitor-bound Trypanosoma brucei MetRS crystal structure suggested that the resistance mutations reposition nearby hydrophobic residues, interfering with compound binding while minimally impacting substrate binding. This is the first report of naturally emerging Cryptosporidium drug resistance, highlighting the need to address the potential for anticryptosporidial resistance and establish strategies to limit its occurrence.


Asunto(s)
Enfermedades de los Bovinos , Criptosporidiosis , Cryptosporidium parvum , Cryptosporidium , Animales , Bovinos , Enfermedades de los Bovinos/tratamiento farmacológico , Niño , Preescolar , Criptosporidiosis/tratamiento farmacológico , Cryptosporidium/genética , Cryptosporidium parvum/genética , Resistencia a Medicamentos/genética , Heces , Humanos
5.
Sci Transl Med ; 12(563)2020 09 30.
Artículo en Inglés | MEDLINE | ID: mdl-32998973

RESUMEN

Cryptosporidium is a protozoan parasite and a leading cause of diarrheal disease and mortality in young children. Currently, there are no fully effective treatments available to cure infection with this diarrheal pathogen. In this study, we report a broad drug repositioning effort that led to the identification of bicyclic azetidines as a new anticryptosporidial series. Members of this series blocked growth in in vitro culture of three Cryptosporidium parvum isolates with EC50 's in 1% serum of <0.4 to 96 nM, had comparable potencies against Cryptosporidium hominis and C. parvum, and was effective in three of four highly susceptible immunosuppressed mice with once-daily dosing administered for 4 days beginning 2 weeks after infection. Comprehensive genetic, biochemical, and chemical studies demonstrated inhibition of C. parvum phenylalanyl-tRNA synthetase (CpPheRS) as the mode of action of this new lead series. Introduction of mutations directly into the C. parvum pheRS gene by CRISPR-Cas9 genome editing resulted in parasites showing high degrees of compound resistance. In vitro, bicyclic azetidines potently inhibited the aminoacylation activity of recombinant ChPheRS. Medicinal chemistry optimization led to the identification of an optimal pharmacokinetic/pharmacodynamic profile for this series. Collectively, these data demonstrate that bicyclic azetidines are a promising series for anticryptosporidial drug development and establish a broad framework to enable target-based drug discovery for this infectious disease.


Asunto(s)
Azetidinas , Criptosporidiosis , Cryptosporidium , Parásitos , Fenilalanina-ARNt Ligasa , Animales , Azetidinas/farmacología , Criptosporidiosis/tratamiento farmacológico , Diarrea , Ratones
6.
mBio ; 11(4)2020 08 04.
Artículo en Inglés | MEDLINE | ID: mdl-32753489

RESUMEN

Invasion of the colon wall by Entamoeba histolytica during amoebic dysentery entails migration of trophozoites through tissue layers that are rich in extracellular matrix. Transcriptional silencing of the E. histolytica surface metalloprotease EhMSP-1 produces hyperadherent less-motile trophozoites that are deficient in forming invadosomes. Reversible protein phosphorylation is often implicated in regulation of cell motility and invadosome formation. To identify such intermediaries of the EhMSP-1-silenced phenotype, here we compared the phosphoproteomes of EhMSP-1-silenced and vector control trophozoites by using quantitative tandem mass spectrometry-based proteomics. Six proteins were found to be differentially phosphorylated in EhMSP-1-silenced and control cells, including EhCoactosin, a member of the ADF/cofilin family of actin-binding proteins, which was more frequently phosphorylated at serine 147. Regulated overexpression of wild-type, phosphomimetic, and nonphosphorylatable EhCoactosin variants was used to test if phosphorylation functions in control of E. histolytica actin dynamics. Each of the overexpressed proteins colocalized with F-actin during E. histolytica phagocytosis. Nonetheless, trophozoites overexpressing an EhCoactosin phosphomimetic mutant formed more and poorly coordinated cell membrane protrusions compared to those in control or cells expressing a nonphosphorylatable mutant, while trophozoites overexpressing nonphosphorylatable EhCoactosin were significantly more motile within a model of mammalian extracellular matrix. Therefore, although EhCoactosin's actin-binding ability appeared unaffected by phosphorylation, EhCoactosin phosphorylation helps to regulate amoebic motility. These data help to understand the mechanisms underlying altered adherence and motility in EhMSP-1-silenced trophozoites and lay the groundwork for identifying kinases and phosphatases critical for control of amoebic invasiveness.IMPORTANCE Invasive amoebiasis, caused by the intestinal parasite Entamoeba histolytica, causes life-threatening diarrhea and liver abscesses, but, for unknown reasons, only approximately 10% of E. histolytica infections become symptomatic. A key requirement of invasion is the ability of the parasite to migrate through tissue layers. Here, we systematically looked for differences in protein phosphorylation between control parasites and a previously identified hyperadherent E. histolytica cell line that has reduced motility. We identified EhCoactosin, an actin-binding protein not previously known to be phosphoregulated, as one of the differentially phosphorylated proteins in E. histolytica and demonstrated that EhCoactosin phosphorylation functions in control of cell membrane dynamics and amoebic motility. This and the additional differentially phosphorylated proteins reported lay the groundwork for identifying kinases and phosphatases that regulate tissue invasiveness.


Asunto(s)
Extensiones de la Superficie Celular/fisiología , Entamoeba histolytica/metabolismo , Proteínas de Microfilamentos/metabolismo , Proteínas Protozoarias/metabolismo , Citoesqueleto de Actina/metabolismo , Actinas/metabolismo , Entamoeba histolytica/genética , Movimiento , Fagocitosis , Fosfoproteínas/genética , Fosforilación , Proteómica , Proteínas Protozoarias/genética
7.
Nat Commun ; 10(1): 1862, 2019 04 23.
Artículo en Inglés | MEDLINE | ID: mdl-31015448

RESUMEN

Cryptosporidiosis is a leading cause of life-threatening diarrhea in children, and the only currently approved drug is ineffective in malnourished children and immunocompromised people. Large-scale phenotypic screens are ongoing to identify anticryptosporidial compounds, but optimal approaches to prioritize inhibitors and establish a mechanistically diverse drug development pipeline are unknown. Here, we present a panel of medium-throughput mode of action assays that enable testing of compounds in several stages of the Cryptosporidium life cycle. Phenotypic profiles are given for thirty-nine anticryptosporidials. Using a clustering algorithm, the compounds sort by phenotypic profile into distinct groups of inhibitors that are either chemical analogs (i.e. same molecular mechanism of action (MMOA)) or known to have similar MMOA. Furthermore, compounds belonging to multiple phenotypic clusters are efficacious in a chronic mouse model of cryptosporidiosis. This suite of phenotypic assays should ensure a drug development pipeline with diverse MMOA without the need to identify underlying mechanisms.


Asunto(s)
Antiparasitarios/farmacología , Criptosporidiosis/tratamiento farmacológico , Cryptosporidium/efectos de los fármacos , Diarrea/tratamiento farmacológico , Inhibidores de Crecimiento/farmacología , Algoritmos , Animales , Antiparasitarios/uso terapéutico , Técnicas de Cultivo de Célula , Línea Celular Tumoral , Análisis por Conglomerados , Criptosporidiosis/parasitología , Cryptosporidium/crecimiento & desarrollo , Diarrea/parasitología , Modelos Animales de Enfermedad , Descubrimiento de Drogas/métodos , Inhibidores de Crecimiento/uso terapéutico , Humanos , Estadios del Ciclo de Vida/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos NOD , Ratones SCID , Fenotipo
8.
Infect Immun ; 86(9)2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-29914929

RESUMEN

Entamoeba histolytica is a protozoan parasite that causes invasive amoebiasis when it invades the human colon. Tissue invasion requires a shift from an adhesive lifestyle in the colonic lumen to a motile and extracellular matrix (ECM) degradative lifestyle in the colonic tissue layers. How the parasite regulates these two lifestyles is largely unknown. Previously, we showed that silencing the E. histolytica surface metalloprotease EhMSP-1 results in parasites that are hyperadherent and less motile. To better understand the molecular mechanism of this phenotype, we now show that the parasites with EhMSP-1 silenced cannot efficiently form specialized dot-like polymerized actin (F actin) structures upon interaction with the human ECM component fibronectin. We characterized these F actin structures and found that they are very short-lived structures that are the sites of fibronectin degradation. Motile mammalian cells form F actin structures called invadosomes that are similar in stability and function to these amoebic actin dots. Therefore, we propose here that E. histolytica forms amoebic invadosomes to facilitate colonic tissue invasion.


Asunto(s)
Actinas/química , Entamoeba histolytica/patogenicidad , Matriz Extracelular/química , Fibronectinas/química , Proteínas Protozoarias/genética , Entamoeba histolytica/genética , Matriz Extracelular/parasitología , Silenciador del Gen , Humanos , Podosomas/metabolismo
9.
J Sci Food Agric ; 96(4): 1297-305, 2016 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-25892666

RESUMEN

BACKGROUND: Blast caused by the fungus Magnaporthe oryzae is a significant disease threat to rice across the world and is especially prevalent in Malaysia. An elite, early-maturing, high-yielding Malaysian rice variety, MR263, is susceptible to blast and was used as the recurrent parent in this study. To improve MR263 disease resistance, the Pongsu Seribu 1 rice variety was used as donor of the blast resistance Pi-7(t), Pi-d(t)1 and Pir2-3(t) genes and qLN2 quantitative trait locus (QTL). The objective was to introgress these blast resistance genes into the background of MR263 using marker-assisted backcrossing with both foreground and background selection. RESULTS: Improved MR263-BR-3-2, MR263-BR-4-3, MR263-BR-13-1 and MR263-BR-26-4 lines carrying the Pi-7(t), Pi-d(t)1 and Pir2-3(t) genes and qLN2 QTL were developed using the simple sequence repeat (SSR) markers RM5961 and RM263 (linked to the blast resistance genes and QTL) for foreground selection and a collection of 65 polymorphic SSR markers for background selection in backcrossed and selfed generations. A background analysis revealed that the highest rate of recurrent parent genome recovery was 96.1% in MR263-BR-4-3 and 94.3% in MR263-BR-3-2. CONCLUSION: The addition of blast resistance genes can be used to improve several Malaysian rice varieties to combat this major disease.


Asunto(s)
Endogamia/métodos , Oryza/genética , Oryza/microbiología , Enfermedades de las Plantas/genética , Enfermedades de las Plantas/microbiología , ADN de Plantas/análisis , Resistencia a la Enfermedad , Genes de Plantas , Marcadores Genéticos , Genotipo , Magnaporthe , Malasia , Repeticiones de Microsatélite , Enfermedades de las Plantas/prevención & control , Especificidad de la Especie
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...